KMDA
$8.89
Kamada Ltd.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung ...
Recent News
Midday Fly By: IEA to release 400M oil barrels, Oracle reports Q3 beat
The major averages were lower near noon, with the Dow dropping over 400 points as traders weigh shifting oil prices and a key inflation report. Markets are trading cautiously amid volatile energy prices and ongoing geopolitical tensions in the Middle East. Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Oil prices, which spiked
Kamada Ltd (KMDA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Outlook
Kamada Ltd (KMDA) reports a 12% revenue increase and outlines future growth strategies amid market challenges.
Kamada Q4 Earnings Call Highlights
Kamada (NASDAQ:KMDA) executives told investors the company delivered “excellent” operational and financial performance in 2025 and entered 2026 with momentum across its commercial portfolio, while also addressing potential logistical concerns tied to the evolving situation in the Middle East. Opera
Kamada (KMDA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Kamada (KMDA) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Kamada (KMDA) Q4 Earnings and Revenues Miss Estimates
Kamada (KMDA) delivered earnings and revenue surprises of -30.80% and -2.29%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?